Evidence map›Paper›PMID 36082341›Full record

ArticleCrohn's & colitis 3602022

Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry.

Edward L Barnes, Parakkal Deepak, Poonam Beniwal-Patel, Laura Raffals, Maia Kayal, Marla Dubinsky, Shannon Chang, Peter D R Higgins, Jennifer I Barr, Joseph Galanko and 4 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Crohn's & colitis 360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06864403 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2025 to 2027Enrolled25ConditionsPouchitis, Pouches, Ileoanal, Pouch, IlealArmsMirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
NCT07756359 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2026 to 2027Enrolled20ConditionsPouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryArmsTirzepatide, Loperamide, Diphenoxylate/Atropine
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Onset of pouchitis after colectomy for ulcerative colitis: reducing the risk.Expert review of gastroenterology & hepatology · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Edward L BarnesDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0001-9894-8796
Parakkal DeepakDivision of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-3436-9784
Poonam Beniwal-PatelDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Laura RaffalsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Maia KayalDivision of Gastroenterology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0002-9640-950X
Marla DubinskyDivision of Pediatric Gastroenterology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0003-4968-5795
Shannon ChangDivision of Gastroenterology and Hepatology, NYU Langone Health, New York, New York, USA.
Peter D R HigginsDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Jennifer I BarrCenter for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA.
Joseph GalankoCenter for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA.
Yue JiangTrinity College of Arts and Sciences, Duke University, Durham, North Carolina, USA.
Raymond K CrossDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Millie D LongDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Hans H HerfarthDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-4268-823X
University of North Carolina at Chapel Hill · USIcahn School of Medicine at Mount Sinai · USDuke University · USMayo Clinic · USMedical College of Wisconsin · USNYU Langone Health · USUniversity of Maryland, Baltimore · USUniversity of Michigan · USWashington University in St. Louis · US

Funding

PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Temitope O. Keku · 1985 to 2026
$30.5M
Treatment Approaches and Outcomes in Pouch-related Disorders after Colectomy for Ulcerative ColitisK23DK127157 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARNES, EDWARD · 2021 to 2025
$1.0M
NIDDK NIH HHS K23 DK127157NIDDK NIH HHS P30 DK034987
6 · The paper itself

Abstract

Background: Much of our understanding about the natural history of pouch-related disorders has been generated from selected populations. We designed a geographically diverse, prospective registry to study the disease course among patients with 1 of 4 inflammatory conditions of the pouch. The primary objectives in this study were to demonstrate the feasibility of a prospective pouch registry and to evaluate the predominant treatment patterns for pouch-related disorders. Methods: We used standardized diagnostic criteria to prospectively enroll patients with acute pouchitis, chronic antibiotic-dependent pouchitis (CADP), chronic antibiotic refractory pouchitis (CARP), or Crohn's disease (CD) of the pouch. We obtained detailed clinical and demographic data at the time of enrollment, along with patient-reported outcome (PRO) measures. Results: We enrolled 318 patients (10% acute pouchitis, 27% CADP, 12% CARP, and 51% CD of the pouch). Among all patients, 55% were on a biologic or small molecule therapy. Patients with CD of the pouch were more likely to use several classes of therapy ( Conclusions: In a population where most patients had refractory inflammatory conditions of the pouch, we established a framework to evaluate PROs and clinical effectiveness. This infrastructure will be valuable for long-term studies of real-world effectiveness for pouch-related disorders.

Indexed as

Crohn’s disease of the pouchileal pouch-anal anastomosispouchitisreal-world effectiveness

Identifiers

PMID36082341
PMCPMC9446900
OpenAlexW4289333432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.